Medicare Enrolled
Dr. Moshe Chasky, M.D.
Hematology & Oncology · Philadelphia, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Chasky from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chasky?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Chasky
Dr. Moshe Chasky is a hematology & oncology specialist in Philadelphia, PA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Chasky performed 66,009 Medicare services across 1,164 unique beneficiaries.
Between the years covered by Open Payments, Dr. Chasky received a total of $23,895 from 101 pharmaceutical and/or device companies across 785 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Chasky is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 10% volume in PA
$23,895 industry payments
Medicare Practice Summary
Medicare Utilization ↗66,009
Medicare services
Top 10% in PA for hematology & oncology
1,164
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,667 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
22,020 | $2 | $21 |
| Denosumab injection (Prolia/Xgeva) | 13,440 | $19 | $68 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
12,900 | $0 | $6 |
| Eflapegrastim injection, 0.1 mg An injection of eflapegrastim-xnst administered at a dose of 0.1 mg. |
4,752 | $25 | $92 |
| Iron infusion (Monoferric) | 3,300 | $17 | $73 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,270 | $0 | $1 |
| Injection, granisetron hydrochloride, 100 mcg | 1,240 | $0 | $25 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,230 | $1 | $122 |
| Pegfilgrastim-apgf injection An injection of pegfilgrastim-apgf, a biosimilar medication. The dose specified is 0.5 mg. |
816 | $87 | $879 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
733 | $103 | $224 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
608 | $13 | $105 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
419 | $12 | $93 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
387 | $110 | $686 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
272 | $66 | $148 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
206 | $61 | $205 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
181 | $24 | $156 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
167 | $23 | $152 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
163 | $1 | $7 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
143 | $53 | $304 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
140 | $11 | $73 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
124 | $64 | $157 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
112 | $2 | $19 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
88 | $27 | $249 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
65 | $140 | $301 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
53 | $107 | $297 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
52 | $54 | $334 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
48 | $1 | $10 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
29 | $133 | $343 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
24 | $1 | $19 |
| New patient office visit, complex (60-74 min) | 15 | $170 | $444 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
12 | $142 | $412 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
6.5% high complexity
91.3% medium
2.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$23,895
Total received (2018-2024)
Avg $3,414/year across 7 years
Top 15% in PA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
101
Companies
785
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,549 (65.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$5,619 (23.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,728 (11.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$8,919
2023
$5,658
2022
$2,635
2021
$1,718
2020
$806
2019
$2,514
2018
$1,646
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Alexion Pharmaceuticals, Inc.
$5,129
Janssen Biotech, Inc.
$242
Incyte Corporation
$183
Novartis Pharmaceuticals Corporation
$180
AstraZeneca Pharmaceuticals LP
$178
ABBVIE INC.
$176
GENZYME CORPORATION
$176
Astellas Pharma US Inc
$173
Daiichi Sankyo Inc.
$168
Eisai Inc.
$158
Regeneron Healthcare Solutions, Inc.
$150
Ipsen Biopharmaceuticals, Inc
$147
GlaxoSmithKline, LLC.
$145
Gilead Sciences, Inc.
$123
Takeda Pharmaceuticals U.S.A., Inc.
$113
Genmab U.S., Inc.
$106
SOBI, INC
$105
Celgene Corporation
$92
Merck Sharp & Dohme LLC
$86
PFIZER INC.
$80
SUN PHARMACEUTICAL INDUSTRIES INC.
$75
Karyopharm Therapeutics Inc.
$71
Genentech USA, Inc.
$70
Lilly USA, LLC
$70
EAGLE PHARMACEUTICALS, INC.
$61
Pharmacosmos Therapeutics Inc.
$60
Sumitomo Pharma America, Inc.
$59
Bayer Healthcare Pharmaceuticals Inc.
$53
Alnylam Pharmaceuticals Inc.
$50
Exelixis Inc.
$44
Mirati Therapeutics, Inc.
$40
Kite Pharma, Inc.
$34
E.R. Squibb & Sons, L.L.C.
$29
RECORDATI_RARE_DISEASES_INC.
$25
Amgen Inc.
$23
Apellis Pharmaceuticals, Inc.
$22
Adaptive Biotechnologies Corporation
$22
Myriad Genetic Laboratories, Inc.
$21
PharmaEssentia USA Corporation
$20
BeiGene USA, Inc.
$20
Stemline Therapeutics Inc.
$19
Tempus AI, Inc
$19
Kyowa Kirin, Inc.
$18
Cumberland Pharmaceuticals, Inc.
$18
ADC Therapeutics America, Inc.
$17
EMD Serono, Inc.
$17
Acrotech Biopharma Inc.
$16
PUMA BIOTECHNOLOGY, INC.
$15
Top 3 companies account for 62.3% of 2024 payments
All-time payments by company (2018-2024) ›
Alexion Pharmaceuticals, Inc.
$5,207
Gilead Sciences, Inc.
$1,828
Novartis Pharmaceuticals Corporation
$1,111
Janssen Scientific Affairs, LLC
$1,090
AstraZeneca Pharmaceuticals LP
$979
E.R. Squibb & Sons, L.L.C.
$824
Genentech USA, Inc.
$699
Amgen Inc.
$656
Takeda Pharmaceuticals U.S.A., Inc.
$629
Janssen Biotech, Inc.
$563
Astellas Pharma US Inc
$543
Celgene Corporation
$534
GENZYME CORPORATION
$507
Lilly USA, LLC
$478
Daiichi Sankyo Inc.
$469
Eisai Inc.
$444
Incyte Corporation
$439
PFIZER INC.
$430
Merck Sharp & Dohme Corporation
$310
Seagen Inc.
$285
Pharmacyclics LLC, An AbbVie Company
$281
Bayer HealthCare Pharmaceuticals Inc.
$268
Merck Sharp & Dohme LLC
$244
GlaxoSmithKline, LLC.
$221
Foundation Medicine, Inc.
$214
EAGLE PHARMACEUTICALS, INC.
$204
Regeneron Healthcare Solutions, Inc.
$192
Ipsen Biopharmaceuticals, Inc
$181
ABBVIE INC.
$176
Boehringer Ingelheim Pharmaceuticals, Inc.
$173
Genmab U.S., Inc.
$167
McKesson Specialty Care Distribution, LLC
$143
BeiGene USA, Inc.
$141
Pharmacosmos Therapeutics Inc.
$138
Karyopharm Therapeutics Inc.
$118
EMD Serono, Inc.
$115
Puma Biotechnology, Inc.
$113
Kite Pharma, Inc.
$106
SOBI, INC
$105
TESARO, Inc.
$98
MorphoSys, US Inc.
$90
Sumitomo Pharma America, Inc.
$88
Exelixis Inc.
$86
Mirati Therapeutics, Inc.
$84
EISAI INC.
$81
Rigel Pharmaceuticals, Inc.
$78
AbbVie Inc.
$75
SUN PHARMACEUTICAL INDUSTRIES INC.
$75
Bayer Healthcare Pharmaceuticals Inc.
$74
Myriad Genetic Laboratories, Inc.
$73
Stemline Therapeutics Inc.
$70
G1 Therapeutics, Inc.
$70
Dendreon Pharmaceuticals LLC
$67
Verastem, Inc.
$63
Kyowa Kirin, Inc.
$60
Pharmacyclics LLC, an AbbVie Company
$58
Janssen Pharmaceuticals, Inc
$55
ADC Therapeutics America, Inc.
$54
Alnylam Pharmaceuticals Inc.
$50
Myovant Sciences Inc.
$48
AbbVie, Inc.
$46
Clovis Oncology, Inc.
$45
Apellis Pharmaceuticals, Inc.
$42
ARRAY BIOPHARMA INC
$41
Seattle Genetics, Inc.
$40
Blueprint Medicines Corporation
$39
Adaptive Biotechnologies Corporation
$39
TerSera Therapeutics LLC
$39
Acrotech Biopharma LLC
$38
PharmaEssentia USA Corporation
$38
Helsinn Therapeutics (U.S.), Inc.
$36
PUMA BIOTECHNOLOGY, INC.
$34
Acrotech Biopharma Inc.
$33
Novocure Inc.
$32
Shire North American Group Inc
$29
ImmunoGen, Inc.
$29
Johnson & Johnson Health Care Systems Inc.
$28
SERVIER PHARMACEUTICALS LLC
$28
SECURA BIO, INC.
$27
RECORDATI_RARE_DISEASES_INC.
$25
JAZZ PHARMACEUTICALS INC.
$24
EUSA Pharma (US) LLC
$21
Secura Bio, Inc.
$21
Aadi Bioscience, Inc.
$20
Aurobindo Pharma USA, Inc.
$20
Jazz Pharmaceuticals Inc.
$20
Dova Pharmaceuticals
$19
Tempus AI, Inc
$19
Blue Earth Diagnostics Limited
$19
Organon LLC
$18
Cumberland Pharmaceuticals, Inc.
$18
Heron Therapeutics, Inc.
$18
Advanced Accelerator Applications
$16
AVEO Pharmaceuticals, Inc.
$15
Clinigen Inc
$15
Taiho Oncology, Inc.
$14
Deciphera Pharmaceuticals Inc.
$14
Acceleron Pharma, Inc.
$14
Emmaus Medical, Inc.
$13
Epizyme, Inc.,
$13
Teva Pharmaceuticals USA, Inc.
$11
Top 3 companies account for 34.1% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AKYNZEO · ALIMTA · ALUNBRIG · AMVUTTRA · AYVAKIT · Abraxane · Alecensa · Aliqopa · Avastin · Axumin · BAVENCIO · BELEODAQ · BENDEKA · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CINVANTI · COPIKTRA · COSELA · CYRAMZA · Cabometyx · Copiktra · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIQUIS · ELITEK · ELZONRIS · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · EXKIVITY · Elahere · Empaveli · Endari · Enhertu · Epkinly · FASLODEX · FOTIVDA · FOUNDATIONONE · FRUZAQLA · FYARRO · Fabhalta · Folotyn · GAUCHER-DISEASE · GAZYVA · GILOTRIF · HYQVIA · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · Imbruvica · Inrebic · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lunsumio · Lutathera · MEKINIST · MONJUVI · MONOFERRIC · MYRISK · Monoferric · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OJJAARA · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · Odomzo · Oncology · Onivyde · Orserdu · PADCEV · PEMAZYRE · PEMFEXY · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · Perjeta · Phesgo · Polivy · Pomalyst · Poteligeo · Proleukin · QINLOCK · REBLOZYL · RETEVMO · Reblozyl · Revlimid · Rezlidhia · Rubraca · SANCUSO · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SOLIRIS · SUTENT · SYLVANT · SYNAGIS · Somatuline Depot · Stivarga · Sylvant · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · TIVDAK · TRUSELTIQ · TUKYSA · Tavalisse · Tibsovo · Tivdak · Trodelvy · ULTOMIRIS · VARUBI · VENCLEXTA · VERZENIO · VONJO · VPRIV · VYXEOS · Vanflyta · Venclexta · Vitrakvi · WELIREG · XALKORI · XARELTO · XOSPATA · XPOVIO · XT CDX · XTANDI · Xofigo · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · ZYTIGA · Zoladex · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (65%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
274
Per 100K population
17.3
County median income
$60,698
Nearest hospital
JEFFERSON HEALTH- NORTHEAST
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Chasky is a mixed practice specialist, with above-average Medicare volume (top 10% in PA), with low-engagement industry engagement in the top 15% of PA peers, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Chasky experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Chasky performed 22,020 darbepoetin injection (aranesp) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Chasky receive payments from pharmaceutical companies?
Yes. Dr. Chasky received a total of $23,895 from 101 companies across 785 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chasky's costs compare to other hematology & oncology specialists in Philadelphia?
Dr. Chasky's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chasky) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Philadelphia
Browse hematology & oncology specialists in Philadelphia ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in PA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in PA
Which PA hematology & oncology specialists receive the most from drug and device companies.
By company
Alexion Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Alexion Pharmaceuticals, Inc.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology